(BW HealthWire) — IDEC Pharmaceuticals Corporation (Nasdaq: IDPH) today announced the receipt of a Complete Review Letter from the U.S. Food and Drug Administration (FDA) following the agency’s review of the Biologics License Application (BLA) for ZEVALIN(TM) (Ibritumomab Tiuxetan).
The company will provide an overview of the ZEVALIN Complete Review Letter and discuss the Company’s strategy for response during a webcast conference call on Thursday, May 10, 2001, at 1:30 PM Pacific Daylight Time (PDT).
The webcast can be accessed by going to IDEC’s web site at idecpharm.cdmail.biz and will be archived and available for replay until close of business on Monday, May 14, 2001.
IDEC Pharmaceuticals focuses on the commercialization and development of targeted therapies for the treatment of cancer and autoimmune diseases. IDEC’s antibody products act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic systems. IDEC Pharmaceuticals has headquarters in San Diego. The company, which is traded on the NASDAQ, is a member of the NASDAQ 100.
IDEC Pharmaceuticals’ press releases are available at no charge through Business Wire’s News on Demand Plus. For a menu of IDEC’s current press releases and quarterly reports or to retrieve a specific release, call 888/329-2309. On the Internet, check the News Center at IDEC’s Web site: http://idecpharm.cdmail.biz.
–30–js/sd* ts/sd
| CONTACT: | IDEC Pharmaceuticals Corporation |
|---|